AstraZeneca: Contrarian Buy After The China Challenge (Rating Upgrade)

When I last wrote about the Anglo-Swedish pharmaceuticals company AstraZeneca (NASDAQ: AZN ) in June, further upside to the stock was already unlikely. This prompted a Hold rating on it, breaking the trend from the previous seven Buy ratings on it since 2022. This Manika is a macroeconomist with over 20 years of experience in industries including investment management, stock broking, investment banking. She also runs the profile Long Term Tips [LTT], which focuses on the generational opportunity in the gree ...